Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F)

被引：1
|
作者：
Yuichi Terawaki
Chikayo Iwaya
Takashi Nomiyama
Dai Shimono
Tsuyoshi Horikawa
Yuki Fujimura-Tanaka
Toru Shigeoka
Nobuya Hamanoue
Ryoko Motonaga
Makito Tanabe
Toshihiko Yanase
Daiji Kawanami
机构：
[1] Fukuoka University,Department of Endocrinology and Diabetes Mellitus, School of Medicine
[2] Futata Tetsuhiro Clinic,undefined
[3] Muta Hospital,undefined
[4] Research Institute for Islet Biology,undefined
[5] Fukuoka University,undefined
来源：
Diabetology International | 2020年 / 11卷
关键词：
Dipeptidyl peptidase-4 inhibitor; Insulin secretagogue; Glucose oscillation; Hypoglycemia; Atherosclerosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：274 / 282
页数：8
相关论文
共 50 条
  • [21] Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis
    Terawaki, Yuichi
    Nomiyama, Takashi
    Takahashi, Hiroyuki
    Tsutsumi, Yoko
    Murase, Kunitaka
    Nagaishi, Ryoko
    Tanabe, Makito
    Kudo, Tadachika
    Kobayashi, Kunihisa
    Yasuno, Tetsuhiko
    Nakashima, Hitoshi
    Yanase, Toshihiko
    DIABETOLOGY & METABOLIC SYNDROME, 2015, 7
  • [22] Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis
    Yuichi Terawaki
    Takashi Nomiyama
    Hiroyuki Takahashi
    Yoko Tsutsumi
    Kunitaka Murase
    Ryoko Nagaishi
    Makito Tanabe
    Tadachika Kudo
    Kunihisa Kobayashi
    Tetsuhiko Yasuno
    Hitoshi Nakashima
    Toshihiko Yanase
    Diabetology & Metabolic Syndrome, 7
  • [23] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
    Hermansen, K.
    Kipnes, M.
    Luo, E.
    Fanurik, D.
    Khatami, H.
    Stein, P.
    DIABETES OBESITY & METABOLISM, 2007, 9 (05): : 733 - 745
  • [24] The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial
    Frederich, Robert
    McNeill, Robert
    Berglind, Niklas
    Fleming, Douglas
    Chen, Roland
    DIABETOLOGY & METABOLIC SYNDROME, 2012, 4
  • [25] Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus
    Ndefo, Uche Anadu
    Okoli, Okwuchukwu
    Erowele, Goldina
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (02) : 103 - 109
  • [26] Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review
    Frandsen, C. S. S.
    Madsbad, S.
    DIABETIC MEDICINE, 2014, 31 (11) : 1293 - 1300
  • [27] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
    Pratley, R. E.
    Kipnes, M. S.
    Fleck, P. R.
    Wilson, C.
    Mekki, Q.
    DIABETES OBESITY & METABOLISM, 2009, 11 (02): : 167 - 176
  • [28] Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: A systematic review and meta-analysis
    Kim, Yeong Gi
    Min, Se Hee
    Hahn, Seokyung
    Oh, Tae Jung
    Park, Kyong Soo
    Cho, Young Min
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 116 : 86 - 95
  • [29] A comparison of intensive insulin therapy and dipeptidyl peptidase-4 inhibitor plus metformin combination in newly diagnosed type 2 diabetes mellitus
    Diri, Halit
    Bolayir, Basak
    Soylu, Hikmet
    Cetin, Sedat
    Simsek, Mehmet
    MINERVA ENDOCRINOLOGY, 2024, 49 (02): : 228 - 230
  • [30] Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes
    Lajara, Rosemarie
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (18) : 2663 - 2671
12345